Adachi, Yoshitaka
Sakai, Toshiyasu
Terakura, Seitaro http://orcid.org/0000-0002-1194-8046
Shiina, Takashi
Suzuki, Shingo
Hamana, Hiroshi
Kishi, Hiroyuki
Sasazuki, Takehiko
Arase, Hisashi
Hanajiri, Ryo
Goto, Tatsunori
Nishida, Tetsuya
Murata, Makoto
Kiyoi, Hitoshi
Funding for this research was provided by:
Japan society for the promotion of science (18k08351)
Japan Agency for Medical Research and Development (17ck0106291h0001, 19ek0510022h0003, 19ek0510022h0003, 21ek0510032h0002, 21ek0510032h0002)
Article History
Received: 2 November 2021
Revised: 6 December 2021
Accepted: 6 December 2021
First Online: 17 January 2022
Declarations
:
: H. Kiyoi: Research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Bristol Myers Squibb., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., CURED Inc. and AbbVie Inc.; honoraria from Astellas Pharma Inc., and Novartis Pharma K.K. The other authors declare no competing financial interests.